

Table S2. Changes in body composition during initial treatment and the introduction of AB or LEN treatment

	AB group (n = 37)			LEN group (n = 57)		
	Initial treatment	Introduction of AB	<i>p</i> value	Initial treatment	Introduction of LEN	<i>p</i> value
SMI (cm ² /m ²)	43.2 (37.8–49.0)	42.9 (36.4–47.7)	0.777	45.0 (39.8–51.4)	46.5 (40.6–50.8)	0.931
SATI (cm ² /m ²)	50.0 (26.2–73.2)	42.8 (30.4–53.8)	0.119	47.1 (26.0–59.0)	52.1 (27.9–67.6)	0.164
VATI (cm ² /m ²)	44.7 (27.6–60.8)	54.7 (36.1–67.2)	0.002	47.0 (27.4–65.4)	48.8 (29.0–64.2)	0.891

Continuous covariates are presented as medians (interquartile range). AB, atezolizumab plus bevacizumab; LEN, Lenvatinib; SMI, skeletal muscle index; SATI, subcutaneous adipose tissue index; VATI, visceral adipose tissue index;